GLP-1 Side Effects: The Complete Guide (2026)

Understanding the GLP-1 side effect landscape

GLP-1 receptor agonists are among the most effective medications for weight loss ever developed, but they are not side-effect free. Understanding what to expect, what is normal, and what requires medical attention is essential for patients making informed treatment decisions. This guide covers the full spectrum of reported side effects, from the very common to the rare but serious.

The most important thing to know upfront: the majority of side effects are gastrointestinal, dose-dependent, and temporary. They tend to be worst during the first few weeks of treatment and after each dose increase. Gradual dose escalation, proper hydration, and dietary adjustments can reduce both the severity and duration of most symptoms. Patients who work with providers that offer structured clinical support, such as MEDVi, FORM Health, or PlushCare, often have better outcomes because side effects are managed proactively.

ClearlyMeds is an independent editorial team. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.

• Most side effects are GI-related and improve over time
• Dose escalation speed is the biggest modifiable risk factor
• Provider support quality directly affects side effect management

Nausea, vomiting, and appetite changes

Nausea is the most commonly reported GLP-1 side effect, affecting 40 to 50% of patients during dose escalation in clinical trials. It is caused by slowed gastric emptying and changes in gut signaling. For most patients, nausea is mild to moderate and peaks in the first 1 to 3 weeks after starting or increasing a dose. Management strategies include eating smaller meals, avoiding greasy foods, staying hydrated, and eating slowly. Ginger tea, peppermint, and in some cases prescription anti-nausea medication (such as ondansetron) can help.

Vomiting occurs in approximately 10 to 15% of patients and is usually tied to eating too much, eating too quickly, or consuming high-fat foods while the stomach is emptying slowly. Persistent vomiting that prevents fluid intake is a medical concern and should be reported to your clinician promptly. Dehydration from repeated vomiting is one of the more serious practical risks of GLP-1 treatment.

Dramatic appetite reduction is technically the intended effect, but some patients experience it as unsettling, especially in the early weeks. The sensation of having almost no interest in food can feel abnormal. This is expected and usually stabilizes as the body adjusts.

Constipation, diarrhea, and digestive issues

Constipation affects roughly 20 to 25% of patients and is driven by two factors: slowed GI motility from the medication and reduced food and fiber intake from appetite suppression. Prevention includes adequate hydration (at least 64 oz of water daily), fiber-rich foods or a fiber supplement, and regular physical activity. Over-the-counter stool softeners or osmotic laxatives can be used if dietary measures are insufficient, but patients should consult their clinician before starting any bowel regimen.

Diarrhea is reported by 15 to 20% of patients, sometimes alternating with constipation. It is more common in the early weeks and often improves with time. Sulfur burps (belching with an egg-like odor) are a distinctive and bothersome symptom reported by a meaningful subset of patients. The exact mechanism is not fully understood, but slowed gastric emptying and changes in gut bacteria may contribute. Eating smaller meals, reducing carbonated beverages, and avoiding sulfur-rich foods (eggs, cruciferous vegetables, red meat) can help.

Bloating and reflux are common companions to other GI symptoms. Patients who previously had no reflux may develop it because a full, slowly-emptying stomach increases pressure on the lower esophageal sphincter. Elevating the head of the bed and avoiding eating within 3 hours of lying down are practical strategies.

Fatigue, muscle loss, and hair thinning

Fatigue is reported by many GLP-1 patients but is often multifactorial. Caloric restriction itself causes fatigue. Dehydration worsens it. Micronutrient deficiencies (B12, iron, vitamin D) can develop when food intake drops substantially. Before attributing fatigue solely to the medication, patients should ensure they are eating enough protein, staying hydrated, sleeping adequately, and getting basic labs checked.

Muscle loss is a legitimate concern during any significant weight loss, not just GLP-1 treatment. Studies show that 25 to 40% of weight lost can come from lean mass rather than fat. The best prevention is adequate protein intake (0.7 to 1g per pound of body weight), resistance training at least 2 to 3 times per week, and gradual rather than extreme caloric restriction. Providers with nutrition support, like FORM Health, are better equipped to help patients preserve muscle.

Hair thinning (telogen effluvium) has been reported, particularly in patients losing weight rapidly. This is primarily a nutritional issue, not a direct drug effect. Ensuring adequate protein, iron, zinc, and biotin intake can reduce the risk. Hair thinning from rapid weight loss is usually temporary, with regrowth occurring once weight and nutrition stabilize.

When to call a doctor and when to go to the ER

Call your prescribing clinician if you experience: persistent nausea or vomiting lasting more than 3 days, inability to meet basic nutrition or hydration needs, new or worsening constipation that does not respond to dietary changes, persistent fatigue that interferes with daily activities, or any symptom that feels significantly different from what you were told to expect.

Go to the emergency room if you experience: severe abdominal pain (especially if radiating to the back, which could indicate pancreatitis), inability to keep any fluids down for more than 24 hours, signs of severe dehydration (dark urine, lightheadedness, rapid pulse, confusion), difficulty breathing or facial swelling (possible allergic reaction), or severe persistent diarrhea with blood.

The rare but serious risks of GLP-1 medications include pancreatitis, gallbladder disease (particularly gallstones during rapid weight loss), and potential thyroid concerns. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 receptor agonists. These risks are uncommon but underscore why proper medical screening before and during treatment matters.

This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.